MAIA Biotechnology, Inc. (MAIA) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
444 WEST LAKE STREET, SUITE 1700 CHICAGO, IL 60606 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 9,601,298 | 7,150,695 | 10,950,927 | |||
| Cash and cash equivalent | 9,601,298 | 7,150,695 | 10,950,927 | |||
| Receivables | ||||||
| Other undisclosed current assets | 551,181 | 413,357 | 857,110 | |||
| Total current assets: | 10,152,479 | 7,564,052 | 11,808,037 | |||
| Noncurrent Assets | ||||||
| Deferred costs | 211,203 | |||||
| Other noncurrent assets | 2,800 | 2,800 | 2,800 | |||
| Total noncurrent assets: | 2,800 | 2,800 | 214,003 | |||
| TOTAL ASSETS: | 10,155,279 | 7,566,852 | 12,022,040 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 3,830,038 | 4,937,153 | 3,268,906 | |||
| Accounts payable | 1,512,436 | 1,638,546 | 1,165,505 | |||
| Accrued liabilities | 2,317,602 | 3,298,607 | 2,103,401 | |||
| Total current liabilities: | 3,830,038 | 4,937,153 | 3,268,906 | |||
| Noncurrent Liabilities | ||||||
| Liabilities, other than long-term debt | ||||||
| Derivative instruments and hedges, liabilities | ||||||
| Other undisclosed noncurrent liabilities | 2,690,605 | 2,152,188 | 245,341 | |||
| Total noncurrent liabilities: | 2,690,605 | 2,152,188 | 245,341 | |||
| Total liabilities: | 6,520,643 | 7,089,341 | 3,514,247 | |||
| Equity | ||||||
| Equity, attributable to parent | 3,634,636 | 477,511 | 8,507,793 | |||
| Common stock | 2,616 | 1,699 | 1,096 | |||
| Additional paid in capital | 90,897,468 | 64,472,249 | 52,729,942 | |||
| Accumulated other comprehensive loss | (30,615) | (16,260) | (15,973) | |||
| Accumulated deficit | (87,234,833) | (63,980,177) | (44,207,272) | |||
| Total equity: | 3,634,636 | 477,511 | 8,507,793 | |||
| TOTAL LIABILITIES AND EQUITY: | 10,155,279 | 7,566,852 | 12,022,040 | |||
Income Statement (P&L) (USD)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
| Operating expenses | (16,957,210) | (20,182,381) | (16,176,201) | ||
| Operating loss: | (16,957,210) | (20,182,381) | (16,176,201) | ||
| Nonoperating income | 318,367 | 34,490 | 1,870 | ||
| Investment income, nonoperating | 318,367 | 34,490 | 1,870 | ||
| Other nonoperating income | |||||
| Interest and debt expense | (6,863) | (6,967) | |||
| Loss from continuing operations before equity method investments, income taxes: | (16,638,843) | (20,154,754) | (16,181,298) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | (6,661,157) | 354,754 | 381,298 | ||
| Loss from continuing operations before income taxes: | (23,300,000) | (19,800,000) | (15,800,000) | ||
| Income tax expense | |||||
| Loss from continuing operations: | (23,300,000) | (19,800,000) | (15,800,000) | ||
| Other undisclosed net income | 45,344 | 27,095 | 30,721 | ||
| Net loss: | (23,254,656) | (19,772,905) | (15,769,279) | ||
| Other undisclosed net loss attributable to parent | |||||
| Net loss attributable to parent: | (23,254,656) | (19,772,905) | (15,769,279) | ||
| Other undisclosed net loss available to common stockholders, basic | (450,578) | ||||
| Net loss available to common stockholders, diluted: | (23,254,656) | (19,772,905) | (16,219,857) | ||
Comprehensive Income (USD)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
| Net loss: | (23,254,656) | (19,772,905) | (15,769,279) | ||
| Comprehensive loss: | (23,254,656) | (19,772,905) | (15,769,279) | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (14,355) | (287) | (466,551) | ||
| Comprehensive loss, net of tax, attributable to parent: | (23,269,011) | (19,773,192) | (16,235,830) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.